exagamglogene autotemcel

FDA Drug Profile — CASGEVY

exagamglogene autotemcel is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including CASGEVY. Available dosage form: injection, suspension.

Drug details

Generic Name
exagamglogene autotemcel
Brand Names
CASGEVY
Application Number
BLA125787
Sponsor
Vertex Pharmaceuticals Incorporated
NDC Codes
2
Dosage Forms
INJECTION, SUSPENSION
Routes
INTRAVENOUS
Active Ingredients
EXAGAMGLOGENE AUTOTEMCEL

Indications and Usage

1. INDICATIONS AND USAGE CASGEVY is indicated for the treatment of patients aged 2 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises transfusion-dependent β - thalassemia (TDT) CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy indicated for the treatment of patients aged 2 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). ( 1 ) transfusion-dependent β-thalassemia (TDT). ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.